Today: 11 April 2026
Subscribe
Browse Category

Pharmaceuticals 10 January 2026 - 11 January 2026

Merck (MRK) stock week ahead: $30 billion Revolution talks and JPMorgan catalysts to watch

Merck (MRK) stock week ahead: $30 billion Revolution talks and JPMorgan catalysts to watch

Merck shares fell 0.4% to $110.53 Friday as reports surfaced of talks to buy Revolution Medicines in a deal valued at $28 billion to $32 billion. Revolution shares jumped 10.7% on the speculation. The Wall Street Journal and Financial Times said the deal would be among the largest pre-commercial biotech acquisitions. Investors await updates at the JPMorgan Healthcare Conference on Monday.
11 January 2026
···
AstraZeneca stock: Nasdaq-100 exit date nears as index flows and JPM conference loom

AstraZeneca stock: Nasdaq-100 exit date nears as index flows and JPM conference loom

AstraZeneca will be removed from the Nasdaq-100 on Jan. 20, replaced by Walmart, Nasdaq said Friday. AstraZeneca shares rose 0.28% in London and 0.68% in New York after the announcement. Index funds are expected to adjust holdings near the effective date, potentially increasing trading volume. AstraZeneca management is set to speak at the JPMorgan Healthcare Conference starting Monday.
11 January 2026
····
Roche stock: $570 million MediLink cancer-drug deal puts Swiss shares back in focus

Roche stock: $570 million MediLink cancer-drug deal puts Swiss shares back in focus

Roche agreed to pay MediLink $570 million upfront and in near-term milestones for ex-China rights to experimental cancer drug YL201. Roche shares closed up 0.4% at 340.80 Swiss francs after the deal was announced. The Swiss SMI index hit a record high. Investors await Roche’s appearance at the JPM Healthcare Conference on Jan. 12 and its full-year earnings on Jan. 29.
11 January 2026
··
Johnson & Johnson stock in focus: Trump drug-price pact and fresh cancer data before Monday

Johnson & Johnson stock in focus: Trump drug-price pact and fresh cancer data before Monday

Johnson & Johnson shares fell 0.7% to $204.39 after announcing a deal with the Trump administration to cut U.S. drug prices in exchange for tariff exemptions. The company will offer some medicines at discounted rates via TrumpRx.gov but did not specify drugs or discount sizes. J&J also unveiled plans for two new U.S. manufacturing plants. Early trial data for its cancer drug amivantamab showed a 70% response rate in a first-line subgroup.
11 January 2026
··
Eli Lilly stock (LLY) slips into JPM Week as Amazon adds rival Wegovy pill — what to watch next

Eli Lilly stock (LLY) slips into JPM Week as Amazon adds rival Wegovy pill — what to watch next

Eli Lilly shares fell 1.99% to $1,063.56 Friday, trailing a record-setting S&P 500. Amazon Pharmacy began selling Novo Nordisk’s Wegovy pill for $149 a month, raising concerns about pricing pressure in obesity drugs. Lilly is set to address investors at the J.P. Morgan Healthcare Conference on Tuesday.
11 January 2026
······
OLMA stock jumps 10% into JPMorgan week — what to watch for Olema Pharmaceuticals

OLMA stock jumps 10% into JPMorgan week — what to watch for Olema Pharmaceuticals

Olema Pharmaceuticals shares jumped 9.8% to $28.08 Friday, with 2.5 million shares traded ahead of the CEO’s Jan. 13 presentation at the J.P. Morgan Healthcare Conference. Citi, UBS, and Piper Sandler issued bullish ratings and price targets up to $60, citing upcoming trial data and potential catalysts. Olema raised $218.5 million in November. The company has no approved products and is advancing two breast cancer drug candidates.
11 January 2026
·
NovaBay Pharmaceuticals stock jumps 102% — what to watch for NBY before Monday

NovaBay Pharmaceuticals stock jumps 102% — what to watch for NBY before Monday

NovaBay Pharmaceuticals shares jumped 102.5% to $19.16 Friday, with volume spiking to 10 million. The surge follows disclosures of pre-funded warrants and convertible preferred stock that could sharply increase the share count. David E. Lazar recently became CEO after leading a strategic investment. Traders await new filings and the U.S. CPI report on Jan. 13.
11 January 2026
··
Revolution Medicines stock in focus as Merck buyout talk hangs over RVMD into JPMorgan week

Revolution Medicines stock in focus as Merck buyout talk hangs over RVMD into JPMorgan week

Revolution Medicines shares jumped 10.7% to $118.64 Friday amid reports Merck is in talks to acquire the company for up to $32 billion, according to the Financial Times. Trading volume hit 20.8 million shares. AbbVie denied it was in discussions after an earlier report, sending Revolution’s stock down 11.5% after hours. The FDA granted Breakthrough Therapy status to Revolution’s lung cancer drug candidate.
11 January 2026
··
Novo Nordisk Class B stock rises after Amazon adds Wegovy pill — what to watch before earnings

Novo Nordisk Class B stock rises after Amazon adds Wegovy pill — what to watch before earnings

Novo Nordisk shares rose 3% to 381.45 crowns in Copenhagen after Amazon Pharmacy began selling its new Wegovy weight-loss pill in the U.S. The pill, approved by the FDA in December, puts Novo ahead of Eli Lilly in the obesity pill market. About 8.95 million shares traded Friday, with prices ranging from 369.0 to 389.8 crowns. Novo will report full-year results on Feb. 4.
10 January 2026
··
AbbVie stock slips into weekend after $1.3 billion charge resets guidance; JPM conference looms

AbbVie stock slips into weekend after $1.3 billion charge resets guidance; JPM conference looms

AbbVie shares fell 1.8% to $220.08 Friday after the company cut its Q4 and 2025 profit forecasts, citing a $1.3 billion charge for acquired R&D and milestone expenses. The company denied rumors of takeover talks with Revolution Medicines. AbbVie will present at the J.P. Morgan Healthcare Conference on Jan. 14 and report earnings on Feb. 4.
10 January 2026
···
Johnson & Johnson stock dips on Trump drug-price deal — what to watch before Monday

Johnson & Johnson stock dips on Trump drug-price deal — what to watch before Monday

Johnson & Johnson shares fell 0.7% to $204.39 Friday after the company agreed to lower U.S. drug prices in exchange for tariff exemptions, with terms undisclosed. J&J will join the TrumpRx.gov platform and said it plans two new U.S. manufacturing sites. The S&P 500 rose 0.65%. Investors await the JPMorgan healthcare conference and J&J’s Jan. 21 earnings call.
10 January 2026
··
Eli Lilly stock slides 2%: Zepbound trial data, TuneLab AI tie-up and what’s next for LLY

Eli Lilly stock slides 2%: Zepbound trial data, TuneLab AI tie-up and what’s next for LLY

Eli Lilly shares fell 2% to $1,063.56 Friday, extending a two-day decline and lagging the broader market. The drop followed late-stage trial results for a Zepbound-Taltz drug combo and news of a $1.2 billion deal to buy Ventyx Biosciences. A Form 4 filing showed Lilly Endowment sold 292,148 shares on January 7. Lilly will present at the J.P. Morgan Healthcare Conference on January 13.
10 January 2026
···
1 … 14 15 16 17 18 … 38

Stock Market Today

  • Dow, S&P 500, Nasdaq futures dip as financial sector stumbles on private credit risks
    April 11, 2026, 10:02 AM EDT. Dow, S&P 500, and Nasdaq futures edged lower as the financial sector suffered heavy losses, led by insurance stocks. Shares of Ares, Arthur J. Gallagher, Aon, and Willis Towers Watson dropped after a report from rating firm A.M. Best warned of growing risks tied to private credit in insurers' balance sheets. The report highlighted vulnerabilities in annuity products, which now often rely on lower-quality, less transparent issuers, including overseas affiliates. It noted a surge in private equity-backed insurers entering the annuity market, attracted by the spread between premia inflows and crediting rates fueled by private credit returns. Rising concerns about the quality and stability of private credit investments are prompting analysts to flag new financial system risks amid broader economic and geopolitical instability.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 11.04.2026

11 April 2026
LIVEMarkets rolling coverageStarted: April 11, 2026, 12:00 AM EDTUpdated: April 11, 2026, 10:12 AM EDT Best Dividend Stock to Buy with $5,000: Coca-Cola (KO) Offers Reliable Income April 11, 2026, 10:12 AM EDT. Investors seeking steady income can consider buying Coca-Cola (NYSE: KO) with $5,000, acquiring about 66 shares at $75.91 each. The beverage giant recently raised its quarterly dividend to $0.53, marking its 64th consecutive annual increase. This longevity highlights Coca-Cola's commitment to shareholders and dividend sustainability, driven by its strong brand and stable market position. While Coca-Cola's 10-year total return trails the broader S&P 500 index, it remains
UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

10 April 2026
London’s FTSE 100 rose 0.38% to 10,644.28 late Friday morning as investors awaited U.S.-Iran talks in Pakistan. Brent crude climbed 1% to $96.83 a barrel, while sterling eased but was on track for its biggest weekly gain since January. The FTSE 250 gained 0.79%. Britain’s 10-year gilt yield stood at 4.807%.
US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

10 April 2026
Dow e-minis slipped 0.15% before Friday’s open, with S&P 500 and Nasdaq 100 futures each down 0.08% as traders awaited March CPI data and watched U.S.-Iran tensions. Economists expect headline CPI to rise 0.9% for March and 3.3% year-on-year. Weekly jobless claims increased to 219,000. Brent crude traded near $97 a barrel, while shipping through the Strait of Hormuz remained well below normal.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 10.04.2026

10 April 2026
LIVEMarkets rolling coverageStarted: April 10, 2026, 12:00 AM EDTUpdated: April 10, 2026, 11:59 PM EDT Orora ASX:ORA Faces Earnings Reset After Saverglass Impact and Middle East Disruptions April 10, 2026, 11:59 PM EDT. Orora (ASX:ORA) shares plunged over 8% in one day following a guidance update that revealed an earnings reset at its Saverglass unit due to Middle East supply chain disruptions and a shutdown at the Ras Al Khaimah glass plant. Despite a sharp short-term loss, Orora's 90-day share price rise exceeds 33%, contrasting a longer-term 10.58% annual total shareholder return decline amid ongoing sector pressures. Trading at A$1.49,
Go toTop